Tudor Investment Corp’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-9,341
| Closed | -$242K | – | 4119 |
|
|
2025
Q4 | $242K | Sell |
9,341
-9,296
| -50% | -$221K | ﹤0.01% | 3178 |
|
|
2025
Q3 | $480K | Buy |
+18,637
| New | +$458K | ﹤0.01% | 2719 |
|
|
2025
Q2 | – | Sell |
-20,964
| Closed | -$521K | – | 3636 |
|
|
2025
Q1 | $521K | Sell |
20,964
-1,685
| -7% | -$40.3K | ﹤0.01% | 2258 |
|
|
2024
Q4 | $427K | Buy |
+22,649
| New | +$398K | ﹤0.01% | 2345 |
|
|
2024
Q2 | – | Sell |
-23,244
| Closed | -$679K | – | 2675 |
|
|
2024
Q1 | $679K | Buy |
+23,244
| New | +$714K | ﹤0.01% | 1514 |
|
|
2023
Q2 | – | Sell |
-24,947
| Closed | -$1.02M | – | 2813 |
|
|
2023
Q1 | $1.02M | Buy |
24,947
+1,095
| +5% | +$43.6K | 0.02% | 1188 |
|
|
2022
Q4 | $921K | Buy |
23,852
+6,244
| +35% | +$304K | 0.02% | 1154 |
|
|
2022
Q3 | $937K | Buy |
+17,608
| New | +$979K | 0.02% | 960 |
|
|
2022
Q2 | – | Sell |
-94,265
| Closed | -$7.19M | – | 2420 |
|
|
2022
Q1 | $7.19M | Buy |
94,265
+49,001
| +108% | +$3.27M | 0.17% | 117 |
|
|
2021
Q4 | $2.72M | Sell |
45,264
-3,482
| -7% | -$192K | 0.05% | 496 |
|
|
2021
Q3 | $2.73M | Buy |
+48,746
| New | +$2.81M | 0.04% | 536 |
|
|
2021
Q2 | – | Sell |
-23,302
| Closed | -$1.63M | – | 1847 |
|
|
2021
Q1 | $1.63M | Buy |
+23,302
| New | +$1.66M | 0.03% | 625 |
|
|
2020
Q2 | – | Sell |
-9,298
| Closed | -$312K | – | 1359 |
|
|
2020
Q1 | $312K | Buy |
+9,298
| New | +$386K | 0.03% | 677 |
|
|
2019
Q4 | – | Sell |
-69,949
| Closed | -$2.66M | – | 1330 |
|
|
2019
Q3 | $2.66M | Sell |
69,949
-36,052
| -34% | -$1.44M | 0.09% | 244 |
|
|
2019
Q2 | $4.61M | Buy |
106,001
+29,013
| +38% | +$1.23M | 0.13% | 108 |
|
|
2019
Q1 | $2.93M | Buy |
76,988
+4,020
| +6% | +$157K | 0.12% | 184 |
|
|
2018
Q4 | $3.14M | Buy |
72,968
+17,083
| +31% | +$797K | 0.06% | 110 |
|
|
2018
Q3 | $2.75M | Buy |
55,885
+22,693
| +68% | +$981K | 0.07% | 201 |
|
|
2018
Q2 | $1.06M | Buy |
+33,192
| New | +$1.15M | 0.04% | 420 |
|
|
2017
Q3 | – | Sell |
-4,887
| Closed | -$233K | – | 1212 |
|
|
2017
Q2 | $233K | Sell |
4,887
-496,583
| -99% | -$23M | 0.01% | 839 |
|
|
2017
Q1 | $22.9M | Buy |
+501,470
| New | +$21.7M | 0.7% | 20 |
|
|
2016
Q1 | – | Sell |
-6,004
| Closed | -$461K | – | 1918 |
|
|
2015
Q4 | $461K | Sell |
6,004
-2,086
| -26% | -$118K | 0.01% | 940 |
|
|
2015
Q3 | $332K | Buy |
+8,090
| New | +$496K | 0.01% | 1036 |
|
|
2014
Q4 | – | Sell |
-9,094
| Closed | -$881K | – | 1566 |
|
|
2014
Q3 | $881K | Buy |
+9,094
| New | +$885K | 0.03% | 353 |
|
Other funds holding PCRX
DPCM
VPM
VCM
Tudor Investment Corp's PCRX Position: Q1 2026 in Review
Tudor Investment Corp sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 9,341 shares — an estimated $242K sold.
Tudor Investment Corp first reported a position in PCRX in Q3 2014 and held it in 24 quarters. The position peaked at $22.9M in Q1 2017. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.
- Tudor Investment Corp reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
- Tudor Investment Corp sold 9,341 Pacira BioSciences shares in Q1 2026, an estimated $242K.
- Tudor Investment Corp first reported a position in Pacira BioSciences in Q3 2014 and held it in 24 quarters.
- Tudor Investment Corp's Pacira BioSciences position peaked at $22.9M in Q1 2017.
- 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.
Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.